University of Calgary

TFE3-rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape (2024) Agaimy A, Acosta AM, Cheng L, Collins K, Fridman E, Schubart C, Williamson SR, et al. Journal article Discovery of Perun (G329.9−0.5): a new, young, Galactic SNR (2024) Smeaton ZJ, Filipović MD, Lazarević S, Alsaberi RZ, Ahmad A, Araya M, Ball BD, et al. Journal article Sclerosing mucoepidermoid carcinoma of salivary glands (2024) Othman BK, Bradová M, Simpson RH, Laco J, Agaimy A, Rito M, Ihrler S, et al. Journal article Neural network and layer-wise relevance propagation reveal how ice hockey protective equipment restricts players’ motion (2024) Lennartz R, Khassetarash A, R. Nigg S, Eskofier B, Nigg BM Journal article Hybrid Teamwork: What We Know and Where We Can Go From Here (2024) Handke L, Aldana A, Costa PL, O’Neill TA Journal article Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials (2024) Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, et al. Journal article Evaluation of a medical student-delivered smoking prevention program utilizing a face-aging mobile app for secondary schools in Germany: The Education Against Tobacco cluster-randomized controlled trial (2024) Brinker TJ, Krieghoff-Henning EI, Suhre JL, Silchmüller MP, Divizieva E, Wilhelm J, Hillebrand G, et al. Journal article Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma (2024) Saner FA, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer TA, Meagher NS, et al. Journal article Correction: Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder Bryant-Li-Bhoj syndrome with 38 additional individuals (European Journal of Human Genetics, (2024), 32, 8, (928-937), 10.1038/s41431-024-01610-1) (2024) Layo-Carris DE, Lubin EE, Sangree AK, Clark KJ, Durham EL, Gonzalez EM, Smith S, et al. Journal article, Erratum Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (2024) Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, Schreiber S, et al. Journal article